ClinicalTrials.gg
CompletedNCT01736176Updated Jul 16, 2021Results posted

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

A Phase 3 interventional study of Levodopa-Carbidopa Intestinal Gel and Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) in Advanced Parkinson's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.

Enrollment
31st of 50
39 · median 56
Started
2013
with 2 others
Phase 3
12 of 51
none open now
Registered
30th of 51
by date
Lead sponsor
3 of 51
AbbVie (prior sponsor, Abbott)

Among the 51 studies testing levodopa in Parkinson Disease, this one is the 31st largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2013, is one of 12 in phase 3, and was the 30th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About levodopa

Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing levodopa in Parkinson Disease, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate change in non-motor symptoms from baseline to Week 12 as measured by the Non-Motor Symptom Scale total score.

03

Conditions studied

  • Advanced Parkinson's Disease

Browse trials for

Keywords

  • Safety and efficacy
  • Advanced Parkinson's disease
  • levodopa-carbidopa intestinal gel,
  • carbidopa
  • levodopa
  • Non-Motor Symptom Scale
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have a diagnosis of idiopathic Parkinson's disease (PD) according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria
  • Demonstrate persistent motor fluctuations in spite of individually optimized treatment
  • Subject must experience a minimum of 3 hours "Off" time

Exclusion criteria

Exclusion Criteria:

  • Subject's PD diagnosis is unclear or there is a suspicion that the subject has a Parkinsonian syndrome such as secondary Parkinsonism (e.g., caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), Parkinson-plus syndrome (e.g., Multiple System Atrophy, Progressive Supranuclear Palsy, Diffuse Lewy Body Disease, Corticobasilar Degeneration), or other neurodegenerative disease that might mimic the symptoms of PD.
  • Subject has undergone neurosurgery for the treatment of Parkinson's disease
  • Subject for whom the placement of a PEG-J tube for LCIG treatment is or is considered a high risk for the PEG-J procedure according to the gastroenterology evaluation (e.g., pathological changes of the gastric wall, inability to bring the gastric wall and abdominal wall together, blood coagulation disorders, peritonitis, acute pancreatitis, paralytic ileus).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Levodopa-Carbidopa Intestinal Gel

    Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant. Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment.

    Drug: Levodopa-Carbidopa Intestinal Gel · Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J) · Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets

Interventions

  • DrugLevodopa-Carbidopa Intestinal Gel

    Drug pages: Levodopa · Carbidopa

    Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube. The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours.

    Also known as: Duopa, Carbidopa-levodopa enteral suspension (CLES)

  • ProcedurePercutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)
  • DrugLevodopa-carbidopa Immediate Release (LC-IR) Tablets

    After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Number of Participants Who Used Healthcare Resources During the First 4 Weeks

    Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The Week 4 version of the questionnaire addressed the following questions during the first four weeks after the PEG-J procedure: 1. Has the subject had a visit to an emergency room? 2. Has the subject had a visit to an urgent care? 3. Has the subject had an outpatient visit to a neurologist? 4. Has the subject had an outpatient visit to a gastroenterologist, surgeon, or interventional radiologist? 5. Has the subject had an outpatient visit to a primary care physician? 6. Has the subject called the nursing support line? 7. Has the subject called a physician?

    Time frame: Weeks 1-4

  2. Number of Participants With Adverse Events

    Adverse events (AEs) related to treatment are those the investigator determined as having a reasonable possibility being related to study drug based on evidence to suggest a causal relationship between the study drug and the adverse event. A severe AE was defined as an adverse event that caused considerable interference with the participant's usual activities and might be incapacitating or life-threatening. Serious AEs were defined as those that were life-threatening or resulted in death, hospitalization or prolongation of hospitalization, a congenital anomaly, persistent or significant disability/incapacity, or important medical events requiring medical or surgical intervention to prevent a serious outcome.

    Time frame: Weeks 1-4 and Overall (from Week 1 through 30 days after the end of the LCIG Treatment Period; median duration of LCIG device exposure was 428 days)

  3. Number of Participants Who Used Healthcare Resources Through Week 60

    Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The standard version of the questionnaire addressed the following questions over the last 3 months: 1. Has the subject had a visit to an emergency room? 2. Has the subject had an outpatient visit to any of the following healthcare providers? 3. Has the subject been visited in his or her place of residence by a health care professional? 4. Has the subject received assistance from either of the following for their Parkinson's disease in their home? 5. Has the subject needed to contact either of the following for immediate assistance related to their Parkinson's disease? 6. Have family members or friends had to miss any paid work due to the subject's Parkinson's disease? 7. Has the subject fallen during the past month?

    Time frame: Week 60

  4. Change From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 60

  5. Change From Baseline in NMSS Cardiovascular Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS cardiovascular including falls domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  6. Change From Baseline in NMSS Sleep/Fatigue Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sleep/fatigue domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  7. Change From Baseline in NMSS Mood/Cognition Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS mood/cognition domain score ranges from 0 to 72 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  8. Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS perceptual problems/hallucinations domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  9. Change From Baseline in NMSS Attention/Memory Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS attention/memory domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  10. Change From Baseline in NMSS Gastrointestinal Tract Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS gastrointestinal tract domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  11. Change From Baseline in NMSS Urinary Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS urinary domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  12. Change From Baseline in NMSS Sexual Function Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sexual function domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  13. Change From Baseline in NMSS Miscellaneous Domain Score

    The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS miscellaneous domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

    Time frame: Baseline and Week 12 and Week 60

  14. Change From Baseline in Mean Daily Normalized "Off" Time Based on Parkinson's Disease Diary

    The Parkinson's Disease Diary was completed by the participant for 3 consecutive days prior to each visit for the full 24 hours of each day. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from time asleep. "Off" time was defined as time when medication has worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. Parkinson's Disease Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.

    Time frame: Baseline and Week 12 and Week 60

  15. Change From Baseline in Mean Daily Normalized "On" Time Without Troublesome Dyskinesia Based on PD Diary

    The PD Diary was completed by the participant for 3 consecutive days prior to each visit. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from sleep. "On" was defined as time when medication was providing benefit with regard to mobility, slowness, and stiffness. "On" time without troublesome dyskinesia is a composite of "On" time without dyskinesia (involuntary twisting, turning movements which are an effect of medication) plus "On" time with non-troublesome dyskinesia (dyskinesia that does not interfere with function or cause meaningful discomfort). PD Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.

    Time frame: Baseline and Week 12 and Week 60

  16. Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

    The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The Total UPDRS score includes 31 items contributing to three subscales: (I) Mentation, Behavior, and Mood; (II) Activities of Daily Living; and (III) Motor Examination. Each question is answered on a scale from 0 (None) to 4 (Severe); Some questions require multiple grades assigned to each extremity. The UPDRS Total score was computed as the sum of these 3 UPDRS subscales and ranged from 0 to 176, with 176 representing the worst (total) disability, and 0 no disability.

    Time frame: Baseline and Week 12 and Week 60

  17. Change From Baseline in UPDRS Part I: Mentation, Behavior, and Mood Score

    The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The mentation, behavior, and mood score includes 4 items addressing intellectual impairment, thought disorder, motivation/initiative, and depression. Each question is answered on a scale from 0 (None) to 4 (Severe). The UPDRS Part I: mentation, behavior, and mood score was computed as the sum of these items and ranged from 0 (not affected) to 16 (most severely affected).

    Time frame: Baseline and Week 12 and Week 60

  18. Change From Baseline in UPDRS Part II: Activities of Daily Living (ADL) Score

    The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The activities of daily living score includes 13 items addressing speech, salivation, swallowing, handwriting, cutting food, dressing, hygiene, turning in bed, falling, freezing, walking, tremor, and sensory complaints. Each question is answered on a scale from 0 (Normal) to 4 (Severe). The UPDRS Part II: activities of daily living score was computed as the sum of these items and ranged from 0 (not affected) to 52 (most severely affected).

    Time frame: Baseline and Week 12 and Week 60

  19. Change From Baseline in UPDRS Part III: Motor Examination Score

    The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The motor examination score includes 17 items addressing speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. Each question is answered on a scale from 0 (Normal) to 4 (Severe), some items include multiple grades for each extremity. The UPDRS Part III: motor examination score was computed as the sum of these items and ranged from 0 (not affected) to 108 (most severely affected).

    Time frame: Baseline and Week 12 and Week 60

  20. Change From Baseline in UPDRS Part IV: Complications of Therapy Score

    The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The complications of therapy section includes 11 items addressing dyskinesia duration, disability, and pain, early morning dystonia, "offs"-predictable, "offs"-unpredictable, "offs"-sudden, "offs"-duration, anorexia-nausea-vomiting, sleep disturbance, and symptomatic orthostasis. Four questions are answered on a scale from 0 (Normal) to 4 (Severe) and seven on a binary scale where 0=No and 1=Yes. The UPDRS Part IV: complications of therapy score was computed as the sum of these items and ranged from 0 (not affected) to 23 (most severely affected).

    Time frame: Baseline and Week 12 and Week 60

  21. Change From Baseline in UPDRS Dyskinesia Items Score

    The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The dyskinesia items score includes questions 32, 33 and 34 from the complications of therapy section of the UPDRS which address dyskinesia duration, disability, and pain. Each question was answered on a scale from 0 (Normal) to 4 (Severe); the UPDRS dyskinesia items score was computed as the sum of these items and ranged from 0 (not affected) to 12 (most severely affected).

    Time frame: Baseline and Week 12 and Week 60

  22. Change From Baseline in UPDRS Part V: Modified Hoehn and Yahr Staging Score

    The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The modified Hoehn and Yahr scale is as follows: * Stage 0: No signs of disease * Stage 1.0: Symptoms are very mild; unilateral involvement only * Stage 1.5: Unilateral and axial involvement * Stage 2: Bilateral involvement without impairment of balance * Stage 2.5: Mild bilateral disease with recovery on pull test * Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent * Stage 4: Severe disability; still able to walk or stand unassisted * Stage 5: Wheelchair bound or bedridden unless aided

    Time frame: Baseline and Week 12 and Week 60

  23. Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Summary Index

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). The PDQ-39 Summary Index (PDQ-SI) is the sum of all answers divided by the highest score possible (i.e., number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0 - 100 scale where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  24. Change From Baseline in PDQ-39 Mobility Domain Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  25. Change From Baseline in PDQ-39 Activities of Daily Living Domain Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  26. Change From Baseline in PDQ-39 Emotional Well-Being Domain Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  27. Change From Baseline in PDQ-39 Stigma Domain Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  28. Change From Baseline in PDQ-39 Social Support Domain Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  29. Change From Baseline in PDQ-39 Cognition Domain Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  30. Change From Baseline in PDQ-39 Communication Domain Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  31. Change From Baseline in PDQ-39 Bodily Discomfort Domain Score

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

    Time frame: Baseline and Week 12 and Week 60

  32. Percentage of Participants With a Patient Global Impression of Change (PGIC) Response of Improved

    The PGIC is a 7-point response scale. Participants were asked to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of "Very much improved," "Much improved" and "Minimally improved" on the PGIC were used to define responders.

    Time frame: Week 12 and Week 60

  33. Treatment Satisfaction Questionnaire Scores

    The Treatment Satisfaction Questionnaire (TSQ) is a single item instrument developed by the Sponsor on which the participant indicated their level of satisfaction or dissatisfaction with their PD treatment. The responses are recorded on a Likert-type scale (Very Satisfied, Satisfied, Somewhat Satisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied).

    Time frame: Week 12 and Week 60

  34. Change From Baseline in Health-related Productivity

    The Health-Related Productivity Questionnaire (HRPQ) is a generic measure of the impact of disease on the ability of the participant to be productive at paid employment or at performance of household chores. Questions inquire about the amount of time they were scheduled/planned to work, the number of the scheduled/planned hours they were able to work and their ability to be productive for the hours of work they did perform. Absenteeism: Number of hours not worked due to PD or it's treatments; Presenteeism: Number of hours of lost productivity while at work due to PD or it's treatments; Total hours lost: Number of hours lost due to absenteeism and presenteeism

    Time frame: Baseline, Week 12 and Week 60

  35. Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12

    CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The between errors score is the number of times the participant revisited a box in which a token was previously found; errors are calculated for 4-, 6-, and 8-box trials. Higher numbers indicate poorer performance.

    Time frame: Baseline and Week 12

  36. Change From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 12

    CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The Strategy score represents the number of times a participant begins a search with the same box for 6- and 8-box problems. Minimum score is 8 and maximum score is 56. Higher numbers indicate poorer performance.

    Time frame: Baseline and Week 12

  37. Change From Baseline in Controlled Oral Word Association Test (COWAT) Verbal Fluency Scores at Week 60

    Letter fluency was assessed using a paper and pen test, in which participants were asked to generate as many words as possible in 60 seconds, starting with the letters F, A, or S. The COWAT All Letters score is the number of words recalled in all post-baseline assessments, regardless of letter used. The COWAT Baseline Letter score is the number of words recalled in post-baseline assessments that used the same letter as at Baseline.

    Time frame: Baseline and Week 60

07

Results

Posted Feb 8, 2017

Participant flow

This study was conducted at 12 sites in the United States that specialized in movement disorders. Participants were levodopa-responsive with advanced Parkinson's disease (PD) and persistent motor fluctuations despite attempts to optimize treatment with oral levodopa-carbidopa and other available anti-PD medications.

Participant flow — Overall Study
MilestoneLevodopa-Carbidopa Intestinal Gel (LCIG)
Started39
Received lcig38
Completed28
Not completed11
Withdrew: Adverse event3
Withdrew: Withdrawal by subject4
Withdrew: Lack of efficacy3
Withdrew: Unable to complete peg placement1

Outcome measures

PrimaryChange From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score-17.6 ± 3.60
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel · Mixed-effect Repeated Measures (MMRM) · p = < 0.001MMRM model included the fixed effects of study site and visit, with baseline score as a covariate, and the baseline-by-visit interaction.
SecondaryNumber of Participants Who Used Healthcare Resources During the First 4 Weeks

Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The Week 4 version of the questionnaire addressed the following questions during the first four weeks after the PEG-J procedure: 1. Has the subject had a visit to an emergency room? 2. Has the subject had a visit to an urgent care? 3. Has the subject had an outpatient visit to a neurologist? 4. Has the subject had an outpatient visit to a gastroenterologist, surgeon, or interventional radiologist? 5. Has the subject had an outpatient visit to a primary care physician? 6. Has the subject called the nursing support line? 7. Has the subject called a physician?

Time frame:
Weeks 1-4
Reported as:
Count of participants · Participants
Number of Participants Who Used Healthcare Resources During the First 4 Weeks
ParticipantsLevodopa-Carbidopa Intestinal Gel
Q1. Emergency Room Visit3
Q2. Urgent Care Visit0
Q3. Neurologist Visit6
Q4. Gastroenterologist, Surgeon, Radiologist Visit11
Q5. Primary Care Physician Visit8
Q6. Called Nursing Support Line9
Q7. Called Physician13
SecondaryNumber of Participants With Adverse Events

Adverse events (AEs) related to treatment are those the investigator determined as having a reasonable possibility being related to study drug based on evidence to suggest a causal relationship between the study drug and the adverse event. A severe AE was defined as an adverse event that caused considerable interference with the participant's usual activities and might be incapacitating or life-threatening. Serious AEs were defined as those that were life-threatening or resulted in death, hospitalization or prolongation of hospitalization, a congenital anomaly, persistent or significant disability/incapacity, or important medical events requiring medical or surgical intervention to prevent a serious outcome.

Time frame:
Weeks 1-4 and Overall (from Week 1 through 30 days after the end of the LCIG Treatment Period; median duration of LCIG device exposure was 428 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsWeek 1-4Overall
Any adverse event2837
AE related to LCIG2635
AE related to oral LC411
Severe adverse event15
Serious adverse event38
AE leading to premature discontinuation15
Gastrointestinal (GI) adverse event2228
Adverse event other than GI2137
Fatal adverse event01
SecondaryNumber of Participants Who Used Healthcare Resources Through Week 60

Use of healthcare resources was assessed by the investigator using the Health Resource Utilization Questionnaire (HRUQ), a questionnaire developed by the Sponsor regarding the use of healthcare resources due to the participant's Parkinson's disease. The standard version of the questionnaire addressed the following questions over the last 3 months: 1. Has the subject had a visit to an emergency room? 2. Has the subject had an outpatient visit to any of the following healthcare providers? 3. Has the subject been visited in his or her place of residence by a health care professional? 4. Has the subject received assistance from either of the following for their Parkinson's disease in their home? 5. Has the subject needed to contact either of the following for immediate assistance related to their Parkinson's disease? 6. Have family members or friends had to miss any paid work due to the subject's Parkinson's disease? 7. Has the subject fallen during the past month?

Time frame:
Week 60
Reported as:
Count of participants · Participants
Number of Participants Who Used Healthcare Resources Through Week 60
ParticipantsLevodopa-Carbidopa Intestinal Gel
Q1. Emergency Room Visit1
Q2. Visit to Primary Care Physician18
Q2. Visit to Gastroenterologist3
Q2. Visit to Interventional Radiologist1
Q2. Visit to Surgeon1
Q2. Visit to Cardiologist1
Q2. Visit to Endocrinologist0
Q2. Visit to Immunologist0
Q2. Visit to Internist1
Q2. Visit to Psychiatrist0
Q2. Visit to Urologist2
Q2. Visit to Psychologist1
Q2. Visit to Social Worker2
Q2. Visit to Other Healthcare Provider10
Q3. Visited by Physician0
Q3. Visited by Nurse or Nurse Practitioner1
Q3. Visited by Physical or Occupational Therapist0
Q4. Received Unpaid Care From Family/Friend10
Q4. Received Care From Paid Caregiver2
Q5. Called 9110
Q5. Called Family/Friend1
Q6. Family/Friends Missed Work2
Q7. Fall During Past Month10
SecondaryChange From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; the total score is obtained by summing the item scores. The NMSS total score ranges from 0 to 360 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Change From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score-11.8 ± 3.95
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel · Mixed-effect Repeated Measures (MMRM) · p = 0.004MMRM model included the fixed effects of study site and visit, with baseline score as a covariate, and the baseline-by-visit interaction.
SecondaryChange From Baseline in NMSS Cardiovascular Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS cardiovascular including falls domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Cardiovascular Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-0.2 ± 0.37
Week 600.5 ± 0.41
SecondaryChange From Baseline in NMSS Sleep/Fatigue Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sleep/fatigue domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Sleep/Fatigue Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-6.0 ± 1.17
Week 60-5.4 ± 1.29
SecondaryChange From Baseline in NMSS Mood/Cognition Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS mood/cognition domain score ranges from 0 to 72 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Mood/Cognition Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 120.0 ± 1.12
Week 600.5 ± 1.24
SecondaryChange From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS perceptual problems/hallucinations domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-0.5 ± 0.38
Week 600.4 ± 0.43
SecondaryChange From Baseline in NMSS Attention/Memory Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS attention/memory domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Attention/Memory Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-2.1 ± 0.80
Week 60-2.2 ± 0.87
SecondaryChange From Baseline in NMSS Gastrointestinal Tract Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS gastrointestinal tract domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Gastrointestinal Tract Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-2.0 ± 0.60
Week 60-1.9 ± 0.67
SecondaryChange From Baseline in NMSS Urinary Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS urinary domain score ranges from 0 to 36 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Urinary Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-2.2 ± 1.07
Week 600.1 ± 1.19
SecondaryChange From Baseline in NMSS Sexual Function Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS sexual function domain score ranges from 0 to 24 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Sexual Function Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-1.8 ± 0.42
Week 60-1.1 ± 0.47
SecondaryChange From Baseline in NMSS Miscellaneous Domain Score

The NMSS measures the frequency and severity of a range of non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous (pain, taste/smell, weight change, excessive sweating). Severity is rated on a scale from 0 (none) to 3 (severe) and frequency is rated on a scale from 1 (rarely) to 4 (very frequent). Item scores are calculated as the product of severity and frequency; domain scores are obtained by summing the item scores. The NMSS miscellaneous domain score ranges from 0 to 48 with a lower score indicating fewer symptoms; a negative change from baseline indicates improvement in symptoms.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in NMSS Miscellaneous Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-3.4 ± 1.00
Week 60-3.4 ± 1.11
SecondaryChange From Baseline in Mean Daily Normalized "Off" Time Based on Parkinson's Disease Diary

The Parkinson's Disease Diary was completed by the participant for 3 consecutive days prior to each visit for the full 24 hours of each day. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from time asleep. "Off" time was defined as time when medication has worn off and was no longer providing benefit with regard to mobility, slowness, and stiffness. Parkinson's Disease Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · hours
Change From Baseline in Mean Daily Normalized "Off" Time Based on Parkinson's Disease Diary
hoursLevodopa-Carbidopa Intestinal Gel
Week 12-4.1 ± 0.39
Week 60-4.9 ± 0.48
SecondaryChange From Baseline in Mean Daily Normalized "On" Time Without Troublesome Dyskinesia Based on PD Diary

The PD Diary was completed by the participant for 3 consecutive days prior to each visit. Participants recorded whether they had been "On," "Off," or "Asleep" and the severity of their dyskinesias (troublesome or not troublesome) for each 30-minute period during their normal waking time and upon awakening from sleep. "On" was defined as time when medication was providing benefit with regard to mobility, slowness, and stiffness. "On" time without troublesome dyskinesia is a composite of "On" time without dyskinesia (involuntary twisting, turning movements which are an effect of medication) plus "On" time with non-troublesome dyskinesia (dyskinesia that does not interfere with function or cause meaningful discomfort). PD Diary times were normalized to a 16-hour waking time to account for variation in participants' sleep time. Normalized PD Diary times at a given visit were calculated as the average normalized time from the PD Diary for the 3 days prior to the visit.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · hours
Change From Baseline in Mean Daily Normalized "On" Time Without Troublesome Dyskinesia Based on PD Diary
hoursLevodopa-Carbidopa Intestinal Gel
Week 123.7 ± 0.48
Week 604.3 ± 0.58
SecondaryChange From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score

The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The Total UPDRS score includes 31 items contributing to three subscales: (I) Mentation, Behavior, and Mood; (II) Activities of Daily Living; and (III) Motor Examination. Each question is answered on a scale from 0 (None) to 4 (Severe); Some questions require multiple grades assigned to each extremity. The UPDRS Total score was computed as the sum of these 3 UPDRS subscales and ranged from 0 to 176, with 176 representing the worst (total) disability, and 0 no disability.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-11.4 ± 1.67
Week 60-7.7 ± 2.26
SecondaryChange From Baseline in UPDRS Part I: Mentation, Behavior, and Mood Score

The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The mentation, behavior, and mood score includes 4 items addressing intellectual impairment, thought disorder, motivation/initiative, and depression. Each question is answered on a scale from 0 (None) to 4 (Severe). The UPDRS Part I: mentation, behavior, and mood score was computed as the sum of these items and ranged from 0 (not affected) to 16 (most severely affected).

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in UPDRS Part I: Mentation, Behavior, and Mood Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-0.3 ± 0.31
Week 60-0.1 ± 0.26
SecondaryChange From Baseline in UPDRS Part II: Activities of Daily Living (ADL) Score

The Unified Parkinson's Disease Rating Scale (UPDRS) is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The activities of daily living score includes 13 items addressing speech, salivation, swallowing, handwriting, cutting food, dressing, hygiene, turning in bed, falling, freezing, walking, tremor, and sensory complaints. Each question is answered on a scale from 0 (Normal) to 4 (Severe). The UPDRS Part II: activities of daily living score was computed as the sum of these items and ranged from 0 (not affected) to 52 (most severely affected).

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in UPDRS Part II: Activities of Daily Living (ADL) Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-5.5 ± 0.89
Week 60-4.7 ± 0.92
SecondaryChange From Baseline in UPDRS Part III: Motor Examination Score

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The motor examination score includes 17 items addressing speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. Each question is answered on a scale from 0 (Normal) to 4 (Severe), some items include multiple grades for each extremity. The UPDRS Part III: motor examination score was computed as the sum of these items and ranged from 0 (not affected) to 108 (most severely affected).

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in UPDRS Part III: Motor Examination Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-5.6 ± 1.19
Week 60-3.6 ± 1.49
SecondaryChange From Baseline in UPDRS Part IV: Complications of Therapy Score

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The complications of therapy section includes 11 items addressing dyskinesia duration, disability, and pain, early morning dystonia, "offs"-predictable, "offs"-unpredictable, "offs"-sudden, "offs"-duration, anorexia-nausea-vomiting, sleep disturbance, and symptomatic orthostasis. Four questions are answered on a scale from 0 (Normal) to 4 (Severe) and seven on a binary scale where 0=No and 1=Yes. The UPDRS Part IV: complications of therapy score was computed as the sum of these items and ranged from 0 (not affected) to 23 (most severely affected).

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in UPDRS Part IV: Complications of Therapy Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-3.5 ± 0.44
Week 60-2.9 ± 0.57
SecondaryChange From Baseline in UPDRS Dyskinesia Items Score

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The dyskinesia items score includes questions 32, 33 and 34 from the complications of therapy section of the UPDRS which address dyskinesia duration, disability, and pain. Each question was answered on a scale from 0 (Normal) to 4 (Severe); the UPDRS dyskinesia items score was computed as the sum of these items and ranged from 0 (not affected) to 12 (most severely affected).

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in UPDRS Dyskinesia Items Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-1.1 ± 0.28
Week 60-0.6 ± 0.36
SecondaryChange From Baseline in UPDRS Part V: Modified Hoehn and Yahr Staging Score

The UPDRS is an investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The UPDRS assessment was performed by an approved, trained rater. The UPDRS was made up of the following sections: * Part I - Mentation, Behavior, and Mood * Part II - Activities of Daily Living * Part III - Motor Examination * Part IV - Complications of Therapy (including dyskinesias) * Part V - Modified Hoehn and Yahr Staging The modified Hoehn and Yahr scale is as follows: * Stage 0: No signs of disease * Stage 1.0: Symptoms are very mild; unilateral involvement only * Stage 1.5: Unilateral and axial involvement * Stage 2: Bilateral involvement without impairment of balance * Stage 2.5: Mild bilateral disease with recovery on pull test * Stage 3: Mild to moderate bilateral disease; some postural instability; physically independent * Stage 4: Severe disability; still able to walk or stand unassisted * Stage 5: Wheelchair bound or bedridden unless aided

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in UPDRS Part V: Modified Hoehn and Yahr Staging Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-0.2 ± 0.10
Week 60-0.2 ± 0.12
SecondaryChange From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Summary Index

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). The PDQ-39 Summary Index (PDQ-SI) is the sum of all answers divided by the highest score possible (i.e., number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0 - 100 scale where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Summary Index
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-11.2 ± 2.75
Week 60-10.2 ± 2.63
SecondaryChange From Baseline in PDQ-39 Mobility Domain Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in PDQ-39 Mobility Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-18.5 ± 4.39
Week 60-19.4 ± 4.21
SecondaryChange From Baseline in PDQ-39 Activities of Daily Living Domain Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in PDQ-39 Activities of Daily Living Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-12.1 ± 4.43
Week 60-11.9 ± 4.23
SecondaryChange From Baseline in PDQ-39 Emotional Well-Being Domain Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in PDQ-39 Emotional Well-Being Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-4.9 ± 3.14
Week 60-6.6 ± 3.74
SecondaryChange From Baseline in PDQ-39 Stigma Domain Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in PDQ-39 Stigma Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-9.5 ± 2.38
Week 60-5.4 ± 3.01
SecondaryChange From Baseline in PDQ-39 Social Support Domain Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in PDQ-39 Social Support Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 121.6 ± 2.62
Week 603.3 ± 2.95
SecondaryChange From Baseline in PDQ-39 Cognition Domain Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in PDQ-39 Cognition Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-8.4 ± 2.23
Week 60-7.3 ± 2.00
SecondaryChange From Baseline in PDQ-39 Communication Domain Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in PDQ-39 Communication Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-13.0 ± 3.24
Week 60-10.8 ± 2.59
SecondaryChange From Baseline in PDQ-39 Bodily Discomfort Domain Score

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing eight domains of health (mobility \[10 items\], activities of daily living \[six items\], emotional wellbeing \[six items\], stigma \[four items\], communication \[three items\] and bodily discomfort \[three items\]) which subjects consider to be adversely affected by the disease. Each item is scored on the following 5-point scale: 0 = Never, 1 = Occasionally, 2 = Sometimes, 3 = Often, 4 = Always (or cannot do at all, if applicable). Domain scores are calculated by summing the answers to the questions in the domain, dividing by the highest score possible and then multiplying by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status and higher scores are associated with the more severe symptoms of the disease such as tremors and stiffness.

Time frame:
Baseline and Week 12 and Week 60
Reported as:
Least squares mean · units on a scale
Change From Baseline in PDQ-39 Bodily Discomfort Domain Score
units on a scaleLevodopa-Carbidopa Intestinal Gel
Week 12-9.6 ± 4.40
Week 60-3.8 ± 3.65
SecondaryPercentage of Participants With a Patient Global Impression of Change (PGIC) Response of Improved

The PGIC is a 7-point response scale. Participants were asked to rate their change in status using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of "Very much improved," "Much improved" and "Minimally improved" on the PGIC were used to define responders.

Time frame:
Week 12 and Week 60
Reported as:
Number · percentage of participants
Percentage of Participants With a Patient Global Impression of Change (PGIC) Response of Improved
percentage of participantsLevodopa-Carbidopa Intestinal Gel
Week 1278.9
Week 6071.1
SecondaryTreatment Satisfaction Questionnaire Scores

The Treatment Satisfaction Questionnaire (TSQ) is a single item instrument developed by the Sponsor on which the participant indicated their level of satisfaction or dissatisfaction with their PD treatment. The responses are recorded on a Likert-type scale (Very Satisfied, Satisfied, Somewhat Satisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied).

Time frame:
Week 12 and Week 60
Reported as:
Count of participants · Participants
Treatment Satisfaction Questionnaire Scores
ParticipantsWeek 12Week 60
Very satisfied1514
Satisfied149
Somewhat satisfied43
Somewhat dissatisfied11
Dissatisfied10
Very dissatisfied01
Missing310
SecondaryChange From Baseline in Health-related Productivity

The Health-Related Productivity Questionnaire (HRPQ) is a generic measure of the impact of disease on the ability of the participant to be productive at paid employment or at performance of household chores. Questions inquire about the amount of time they were scheduled/planned to work, the number of the scheduled/planned hours they were able to work and their ability to be productive for the hours of work they did perform. Absenteeism: Number of hours not worked due to PD or it's treatments; Presenteeism: Number of hours of lost productivity while at work due to PD or it's treatments; Total hours lost: Number of hours lost due to absenteeism and presenteeism

Time frame:
Baseline, Week 12 and Week 60
Reported as:
Mean · hours
Change From Baseline in Health-related Productivity
hoursWeek 12Week 60
Workplace Work Lost - Absenteeism-2.1 ± 4.63-5.2 ± 6.27
Household Work Lost - Absenteeism-3.5 ± 11.19-1.9 ± 8.38
Workplace Work Lost - Presenteeism-0.8 ± 13.04-0.3 ± 3.87
Household Work Lost - Presenteeism-1.8 ± 6.42-1.9 ± 5.42
Total Workplace Work Lost-3.0 ± 8.87-5.5 ± 4.50
Total Household Work Lost-5.3 ± 15.69-3.8 ± 11.26
SecondaryChange From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12

CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The between errors score is the number of times the participant revisited a box in which a token was previously found; errors are calculated for 4-, 6-, and 8-box trials. Higher numbers indicate poorer performance.

Time frame:
Baseline and Week 12
Reported as:
Mean · errors
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12
errorsLevodopa-Carbidopa Intestinal Gel
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12-0.6 ± 7.73
SecondaryChange From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 12

CANTAB is a computer-based test of the participant's ability to retain spatial information and to manipulate remembered items in working memory. The Spatial Working Memory module requires that subjects find a blue token in a series of displayed boxes and use these to fill up an empty column, while not returning to boxes where a blue token has been previously found. The Strategy score represents the number of times a participant begins a search with the same box for 6- and 8-box problems. Minimum score is 8 and maximum score is 56. Higher numbers indicate poorer performance.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 12
units on a scaleLevodopa-Carbidopa Intestinal Gel
Change From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 120.8 ± 2.31
SecondaryChange From Baseline in Controlled Oral Word Association Test (COWAT) Verbal Fluency Scores at Week 60

Letter fluency was assessed using a paper and pen test, in which participants were asked to generate as many words as possible in 60 seconds, starting with the letters F, A, or S. The COWAT All Letters score is the number of words recalled in all post-baseline assessments, regardless of letter used. The COWAT Baseline Letter score is the number of words recalled in post-baseline assessments that used the same letter as at Baseline.

Time frame:
Baseline and Week 60
Reported as:
Mean · words
Change From Baseline in Controlled Oral Word Association Test (COWAT) Verbal Fluency Scores at Week 60
wordsLevodopa-Carbidopa Intestinal Gel
All Letters Score-0.5 ± 4.80
Baseline Letter Score-1.8 ± 4.03

Adverse events

Collected over Weeks 1-4 and Overall (from Week 1 through 30 days after the end of the LCIG Treatment Period; median duration of LCIG device exposure was 428 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levodopa-Carbidopa Intestinal Gel—8/39 (20.5%)36/39 (92.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventLevodopa-Carbidopa Intestinal Gel
ATRIAL FIBRILLATIONCardiac disorders1/39
CARDIAC FAILURE CONGESTIVECardiac disorders1/39
INTERNAL HERNIAGastrointestinal disorders1/39
PERITONITISInfections and infestations1/39
OSTEOARTHRITISMusculoskeletal and connective tissue disorders1/39
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/39
RADICULOPATHYNervous system disorders1/39
SEDATIONNervous system disorders1/39
ANXIETYPsychiatric disorders1/39
MAJOR DEPRESSIONPsychiatric disorders1/39
Most frequent other events
Showing 10 of 178
Most frequent other events
EventLevodopa-Carbidopa Intestinal Gel
PROCEDURAL PAINInjury, poisoning and procedural complications13/39
STOMA SITE INFECTIONInfections and infestations11/39
STOMA SITE PAINInjury, poisoning and procedural complications9/39
STOMA SITE ERYTHEMAInjury, poisoning and procedural complications8/39
FALLInjury, poisoning and procedural complications7/39
WEIGHT DECREASEDInvestigations7/39
ANXIETYPsychiatric disorders7/39
URINARY TRACT INFECTIONInfections and infestations6/39
ORTHOSTATIC HYPOTENSIONVascular disorders5/39
FLATULENCEGastrointestinal disorders4/39

Baseline characteristics

Age, Continuous
Age, Continuous(years)Levodopa-Carbidopa Intestinal Gel
Mean64.3 ± 10.23
Age, Customized
Age, Customized(Participants)Levodopa-Carbidopa Intestinal Gel
< 65 years17
≥ 65 years22
Sex: Female, Male
Sex: Female, Male(Participants)Levodopa-Carbidopa Intestinal Gel
Female16
Male23
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Levodopa-Carbidopa Intestinal Gel
White36
Black or African American1
Asian2
American Indian or Alaska Native0
Native Hawaiian or other Pacific Islander0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Levodopa-Carbidopa Intestinal Gel
Hispanic or Latino2
Not Hispanic or Latino37
Duration of PD
Duration of PD(years)Levodopa-Carbidopa Intestinal Gel
Mean11.5 ± 5.34
PD Symptoms Present
PD Symptoms Present(Participants)Levodopa-Carbidopa Intestinal Gel
Bradykinesia37
Muscular rigidity33
Resting tremor25
Postural instability22
Non-Motor Symptoms Scale (NMSS) Total Score
Non-Motor Symptoms Scale (NMSS) Total Score(units on a scale)Levodopa-Carbidopa Intestinal Gel
Mean48.3 ± 35.63
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Standaert DG, Rodriguez RL, Slevin JT, Lobatz M, Eaton S, Chatamra K, Facheris MF, Hall C, Sail K, Jalundhwala YJ, Benesh J. Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease. Mov Disord Clin Pract. 2017 Nov-Dec;4(6):829-837. doi: 10.1002/mdc3.12526. Epub 2017 Sep 20. PubMed 29242809 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Mar 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2012
First posted
Nov 29, 2012
Start
Mar 2013
Primary completionActual
Mar 2015
CompletionActual
Dec 2015
Results first posted
Feb 8, 2017
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01736176
Responsible party
Sponsor
First posted
Nov 29, 2012
Start date
Mar 2013
Primary completion
Mar 2015
Completion
Dec 2015
Results posted
Feb 8, 2017
Last update
Jul 16, 2021

Study contacts

Janet Benesh, BS
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa

Start the discussion